Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non-Current Assets (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Other Non-Current Assets for 7 consecutive years, with $9.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 115.63% to $9.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.2 million through Dec 2025, up 115.63% year-over-year, with the annual reading at $9.2 million for FY2025, 115.63% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $9.2 million at 4D Molecular Therapeutics, down from $9.4 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $9.4 million in Q2 2025, with the low at $602000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $2.8 million, with a median of $1.1 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets plummeted 38.81% in 2024, then skyrocketed 813.49% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $602000.0 in 2021, then skyrocketed by 79.4% to $1.1 million in 2022, then crashed by 36.67% to $684000.0 in 2023, then skyrocketed by 522.95% to $4.3 million in 2024, then soared by 115.63% to $9.2 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $9.2 million, $9.4 million, and $9.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.